Open in interactive viewer → charts, metric popovers & call review

LifeMD's Third Reset: Trading 88% Gross Margins for a Pharmacy It Owns

Revenue and EBITDA guidance slashed, a revenue-recognition clean-up, and a quiet abandonment of the insurance story — wrapped around a genuinely better unit economic model
LFMD · Earnings Call · 2026-11-12

The Third Reset

Justin Schreiber did not ease into it. The first substantive sentence of his prepared remarks was the concession: “Last quarter, I told you we expected to exit the year at a $250 million revenue run rate. We won't. We now expect to exit at roughly a $200 million revenue run rate.” — Justin Schreiber, Chairman and Chief Executive Officer · 2026-11-12 Revenue came in at $44.6 million against a $48–51 million guide — down 7% year over year — and the full-year outlook was cut from $205.5–212.5 million to $188–191 million, with adjusted EBITDA swinging from roughly breakeven to negative $10.6–12.6 million. This is not the first time. In November 2025 the guide came down on RexMD customer acquisition costs. In August 2026 analysts were already asking about "the guidance cut." And in March of this year the CFO laid out a path to $25 million of annualized EBITDA exiting 2026 — a number that has now fully evaporated. Three resets in four quarters is no longer a bump; it is a pattern, and the market has priced it as one. The reasons given are three: branded GLP-1 fulfillment arrangements landed later in the quarter than modeled, marketing was deliberately cut by nearly a third sequentially, and early-2026 patient cohorts underperformed, prompting management to pause spend until repriced cohorts proved out.

The Footnote That Matters More Than the Miss

The revenue miss is arithmetic. The disclosure buried in the CFO's prepared remarks is the more uncomfortable item:

We identified some immaterial errors in how we recorded net revenues in certain arrangements with our third-party pharmacy providers. The errors primarily affected 2024 and 2025.

Atul Kavthekar, Chief Financial Officer · 2026-11-12
This is the second such clean-up in four quarters — in November 2025 there was a $1.1 million revision to prior periods with the same third-party pharmacy flavor. When a company is simultaneously asking investors to accept a radically different revenue-recognition basis, a revenue-recognition error in the immediately preceding two years is not a footnote. It is the whole credibility question, and it arrived alongside a 10-Q filed days later than the market expected.

The Principal-Agent Switch: 88% to 57%

Here is the substantive strategic change. LifeMD now fulfills branded GLP-1s — Wegovy, Ozempic, Zepbound, Foundayo — directly through its own pharmacy under arrangements with Novo Nordisk and Eli Lilly. It buys inventory and acts as principal, so patient-pay amounts now hit the top line gross. The reported gross margin, which sat at 88.2% as recently as the last reported quarter, is going to fall a long way: “By the time we get to the end of 2027... I would not be surprised. I think investors should be expecting something that is going to be kind of in the mid- to low 60s and potentially even down into the high 50s. But that's not necessarily an indication of a diminishing economic return.” — Justin Schreiber, Chairman and Chief Executive Officer · 2026-11-12 He is directionally right, and the Street has seen this movie before — Hims management made the identical argument about branded versus compounded economics. The key detail is the CFO's admission that in the prior quarter LifeMD earned zero on branded dispenses, so every incremental fill is now pure gross profit: “this is all purely incremental EBITDA and gross profit margin for us on these products.” — Atul Kavthekar, Chief Financial Officer · 2026-11-12 The accounting optics get worse while the economics get better. That is a genuinely difficult thing to ask an $80 million market cap to underwrite, especially with working capital now required to float branded inventory — the reason for the new $12.5 million Avenue Capital term loan replacing the Citizens revolver.

What Vanished: The Insurance Story

The most revealing thing in this transcript is something nobody said. For roughly five consecutive quarters, payer coverage was the central pillar of the LifeMD narrative — insurance access, Medicare Bridge, 100-plus plans, 220 million covered lives, a 33% customer acquisition cost reduction from turning insurance on. In March the CEO said flatly: “I think you're going to see the business move more and more towards commercial and government insurance patients over the coming quarters.” — Justin Schreiber, Chairman and Chief Executive Officer · 2026-03-09 Predating even that, the May call framed the whole transformation as a mix shift, not a retreat: “In 2025 we had heavy use of compounded GLP-1s. We have continued to migrate this business to where we think the future is-around branded drugs-and that is really the delta you are seeing.” — Atul Kavikar, Chief Financial Officer · 2026-05-06 Asked directly this quarter whether enterprise means selling into health plans and self-insured employers, the answer reversed the entire frame:

We plan to really lean into the self-pay world, Dave. So, not what Omada does, where you're integrated into a benefits plan.

Justin Schreiber, Chairman and Chief Executive Officer · 2026-11-12
The word health plan survives in this quarter's keyword set only as a low-conviction remnant. Medicare Bridge — which in May was described as something not even built into the model — now merits a single sentence about ongoing support. Meanwhile pricing change and marketing spend dominate: the introductory month cut from $75 to $39, multi-month plan selection up from ~25% to ~85%, acquisition cost down 40% from a June peak. That is a real, measurable improvement in cohort quality. But it is a consumer-subscription business again, not the payer-infrastructure business investors were sold.

What Is Genuinely New

Three things, and they are worth taking seriously. First, the AT&T partnership: 100 million wireless and fiber customers plus 110,000 employees eligible for a complimentary membership, live in 11 states (~29 million reach), national in January, with a first dedicated email to ~6 million customers on November 2. Second, next-generation branded obesity medicine — CagriSema and its amylin analog mechanism, filing accepted, decision expected shortly, 22.7% weight loss at 68 weeks. Management's argument that proprietary fixed-dose combinations cannot be compounded is the strongest strategic point on the call, because it narrows the field against the hundreds of direct-marketing competitors that gutted LifeMD's pricing power. Third, six FDA-permitted peptides out of the 503A pharmacy, launching early next year. Globally, that positioning is not contrarian: oral GLP 1 names are up sharply over 90 days and GLP 1 growth exposure trades at a premium. The category is being rewarded. LifeMD is not.

The Tape Is the Verdict

Shares are down 52.7% over 90 trading days, from a July 13 peak of $4.76 — that entire slide is one uninterrupted 17-week decline, and the stock sits 92.8% below its 2021 high of $30.55. At 1.0x revenue, down 29% year over year, the market is valuing the enterprise at barely its own sales line. The balance sheet is at least intact: $21.9 million cash, no debt at quarter end, and roughly $20 million of effective net cash. The bull case reduces to a single testable proposition: management claims it can grow the patient base and revenue approximately 30% in 2027 on roughly today's fixed overhead. If the AT&T channel delivers at a fraction of paid-media CAC, if CagriSema lands into a less-crowded field, and if the pharmacy keeps adding third-party volume from virtual-care platforms, the operating leverage is real. If the third reset becomes the fourth, the self-pay pivot will look less like discipline and more like a retreat from every channel that required someone else's permission.